Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Search by condition
Search By:
32 results
  • Breast Cancer, Ovarian Cancer, Cervical Cancer, Head and Neck Cancer

21-689          Phase I

A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer

  • Pancreatic Cancer, Head and Neck Cancer, Breast Cancer, Thyroid Cancer, Sarcoma, Ovarian Cancer, Kidney Cancer, Liver Cancer, Lung Cancer

23-301          Phase I

A First-in-Human, Open-label, Multicenter, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PYX-201 in Participants with Advanced Solid Tumors

  • Breast Cancer

23-633          Phase II

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination with Anti-cancer Agents in Patients with Advanced Solid Malignancies (PETRA)

  • Prostate Cancer, Pancreatic Cancer, Ovarian Cancer, Lung Cancer, Esophageal Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Head and Neck Cancer

24-114          Phase I

A Phase 1 Trial Investigating LY4101174, an Antibody-Drug Conjugate Targeting Nectin-4, in Participants with Recurrent, Advanced or Metastatic Solid Tumors

  • Prostate Cancer, Lung Cancer, Colorectal Cancer, Breast Cancer, Bladder Cancer

23-452          Phase I

A Phase 1, First-in-Human, Dose Escalation and Expansion Study of FX-909 in Patients with Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma

  • Ovarian Cancer, Melanoma, Lung Cancer, Endometrial Cancer, Breast Cancer, Bladder Cancer, Uterine Cancer

22-430          Phase II

A Phase 1/2 First-in-Human Study of the Safety and Efficacy of IMC-F106C as a Single Agent and in Combination with Checkpoint Inhibitors in HLA-A*02:01-Positive Participants with Advanced PRAME-Positive Cancers

  • Liver Cancer, Endometrial Cancer, Breast Cancer, Bladder Cancer

24-666          Phase II

A Phase 1/2 Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors Harboring FGFR2 and/or FGFR3 Genetic Alterations

  • Lung Cancer, Ovarian Cancer, Gastric (Stomach) Cancer, Esophageal Cancer, Breast Cancer, Bladder Cancer

23-679          Phase II

A Phase 1/2 Study of PRO1107 in Patients with Advanced Solid Tumors

  • Melanoma, Lung Cancer, Breast Cancer, Ovarian Cancer, Prostate Cancer, Colorectal Cancer

22-577          Phase II

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation and Expansion Study of STAR0602, a Selective T Cell Receptor (TCR)-targeting, Bifunctional Antibody-fusion Molecule, in Subjects with Unresectable, Locally Advanced, or Metastatic Solid Tumors that are Antigen-rich (START-001)

  • Breast Cancer, Bladder Cancer, Melanoma, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer

21-329          Phase II

A Phase 1a Open-Label, Dose-Escalation, and a Phase 2 Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of ST-067 Administered Subcutaneously as Monotherapy in Patients with Relapsed or Refractory Solid Tumors

Showing 1 - 10 of 32 results